Influence of erythropoietin therapy on serum prohepcidin levels in dialysis patients

Medical Science Monitor

Volumn 15, Issue 11, 2009, Pages

  Arabul, Mahmut ^a   Gullulu, Mustafa ^a   Yilmaz, Yusuf ^a   Eren, Mehmet Ali ^a   Baran, Bulent ^a   Gul, Cuma Bulent ^a   Kocamaz, Guzin ^a   Dilek, Kamil ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Anemia; Dialysis; End stage renal disease; Erythropoietin; Hepcidin

Indexed keywords

ERYTHROPOIETIN; FERRITIN; FERROUS GLUCONATE; HEMOGLOBIN; IRON SACCHARATE; PEPTIDE HORMONE; PROHEPCIDIN;

ABSENCE OF SIDE EFFECTS; ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFECT; ERYTHROCYTE; FEMALE; FOLLOW UP; HEMATOCRIT; HEMODIALYSIS; HEMODIALYSIS PATIENT; HORMONE BLOOD LEVEL; HUMAN; IRON STORAGE; KIDNEY FAILURE; LEUKOCYTE; MALE; PERITONEAL DIALYSIS; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE;

ANTIMICROBIAL CATIONIC PEPTIDES; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, PARENTERAL; IRON; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROTEIN PRECURSORS; RENAL DIALYSIS; TIME FACTORS;

EID: 71649111604     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Dowling TC: Prevalence, etiology, and consequences of anemia and clinical and economic benefits of anemia correction in patients with chronic kidney disease: an overview. Am J Health Syst Pharm, 2007; 64: S3-7
2. Paoletti E, Cannella G: Update on erythropoietin treatment: should hemoglobin be normalized in patients with chronic kidney disease? J Am Soc Nephrol, 2006; 17: S74-77
3. Santoro A, Canova C: Anemia and erythropoietin treatment in chronic kidney diseases. Minerva Urol Nefrol, 2005; 57: 23-31 (Pubitemid 40904972)
4. Strippoli GF, Navaneethan SD, Craig JC: Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease. Cochrane Database Syst Rev, 2006; 4: CD003967
5. Besarab A, Reyes CM, Hornberger J: Meta-analysis of subcutaneous versus intravenous EPO in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis, 2002; 40: 439-446 (Pubitemid 34971270)
6. Koul D, Dhar S, Chen-Scarabelli C et al: Erythropoietin: new horizon in cardiovascular medicine. Recent Patents Cardiovasc Drug Discov, 2007; 2: 5-12 (Pubitemid 46813410)
7. Park CH, Valore EV, Waring AJ, Ganz T: Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem, 2001; 276: 7806-7810 (Pubitemid 37385573)
8. Kemna EH, Tjalsma H, Willems HL, Swinkels DW: Hepcidin: from discovery to differential diagnosis. Haematologica, 2008; 93: 90-97
9. Hsu SP, Chiang CK, Chien CT, Hung KY: Plasma prohepcidin positively correlates with hematocrit in chronic hemodialysis patients. Blood Purif, 2006; 24: 311-316
10. Eleftheriadis T, Kartsios C, Liakopoulos V et al: Does hepcidin affect erythropoiesis in hemodialysis patients? Acta Haematol, 2006; 116: 238-244
11. Małyszko J, Małyszko JS, Hryszko T et al: Is hepcidin a link between anemia, inflammation and liver function in hemodialyzed patients? Am J Nephrol, 2005; 25: 586-590
12. Kato A, Tsuji T, Luo J et al: Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients. Am J Nephrol, 2008; 28: 115-121 (Pubitemid 350126501)
13. Fein E, Merle U, Ehehalt R et al: Regulation of hepcidin in HepG2 and RINm5F cells. Peptides, 2007; 28: 951-957 (Pubitemid 46654432)
14. Pinto JP, Ribeiro S, Pontes H et al: Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signalling and regulation of C/EBP{alpha}. Blood, 2008; 111: 5727-5733
15. Malyszko J, Mysliwiec M: Hepcidin in anemia and inflammation in chronic kidney disease. Kidney Blood Press Res, 2007; 30: 15-30 (Pubitemid 46272377)
16. De Domenico I, Ward DM, Kaplan J: Hepcidin regulation: ironing out the details. J Clin Invest, 2007; 117: 1755-1758 (Pubitemid 47036308)